# Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.

> **NCT03402815** · PHASE4 · COMPLETED · sponsor: **University Of Perugia** · enrollment: 22 (actual)

## Conditions studied

- HIV Infection With Other Conditions
- Cardiovascular Risk Factor
- Atherosclerosis
- Inflammation

## Interventions

- **DRUG:** Maraviroc 300 mg

## Key facts

- **NCT ID:** NCT03402815
- **Lead sponsor:** University Of Perugia
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-01
- **Primary completion:** 2017-04-30
- **Final completion:** 2017-09-30
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03402815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03402815, "Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03402815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*